EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of$ 0.55. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -5.45%. A quarter ago, it was expected that this drug delivery technology company would post a loss of$ 0.34 per share when it actually produced a loss of $0.55, delivering a surprise of -61.76%. Over the last fo ...